Current intensive treatment has changed the historically high risk of TCF3-PBX1 childhood ALL that was in part ascribed to central nervous system (CNS) involvement and relapse in favorable and intermediate risk cases [46,47]. This evidence concerns the gene PBX1 and acute lymphoblastic leukemia.